Tag Archive for: cancer immunotherapy

P‑PSMA‑101 CAR‑T Therapy in Advanced Prostate Cancer: Early Results from a Phase 1 Trial

P‑PSMA‑101 is an experimental CAR‑T cell therapy being tested in men with metastatic castration‑resistant prostate cancer (mCRPC) who have already received multiple standard treatments (up to 10 before enrollment). In the phase 1 trial, 33 men with heavily pretreated mCRPC received P‑PSMA‑101, an autologous PSMA‑targeted CAR‑T product enriched in stem‑cell‑like memory T cells and engineered […]

EBNK-001: Pioneering Off-the-Shelf NK Cell Therapy for Solid Tumors

EBNK-001 represents a promising advancement in cancer immunotherapy as an “off-the-shelf” allogeneic natural killer (NK) cell product designed for multi-dose administration in patients with advanced solid tumors. Unlike autologous therapies that require individual patient cell harvesting and processing, EBNK-001 leverages healthy donor-derived NK cells, enabling immediate availability without lengthy manufacturing delays. This off-the-shelf approach addresses […]

Nanotech Advancement: Relief from Prostate Cancer Bone Pain on the Horizon

A promising study published this month in Science Advances introduces a promising “neuroimmunotherapy” nanocarrier called LipoNCs@pGSDMB, designed precisely for bone metastases like those in prostate cancer. This tiny, smart drug delivery system activates only in the high-oxidative-stress environment of bone tumors, fusing directly with cancer cell membranes to release its payload straight into the cell’s […]

A-CAR032: a STEAP2-Targeted Armored CAR-T Enters First-in-Human Trial for Advanced Prostate Cancer

A new Phase 1 clinical trial is testing A-CAR032, a CAR-T cell therapy, in patients with metastatic castration-resistant prostate cancer, or mCRPC. This first-in-human study targets STEAP2, a protein found on nearly all prostate cancer cells, including those that have spread to bones and lymph nodes. Prostate cancer creates a tough environment for immune cells […]

SL-28 Phase 1/2 Trial: A Potential Breakthrough for Advanced Solid Tumors

SL-28 is a new type of donor cell therapy called Leukocyte-Tells. These cells come from healthy donors and get prepared outside the body to better fight cancer. They make more cancer-killing compounds, eat tumor cells, release enzymes, produce helpful signals, and move well toward tumors. Unlike other cell therapies, SL-28 does not need to match […]

KAIST In Situ CAR-Macrophage Therapy

The KAIST team has introduced a highly innovative form of cancer immunotherapy that turns the body’s own macrophages into potent, targeted cancer killers directly inside solid tumours. Instead of the classic, laborious route of extracting immune cells from a patient, engineering them in a lab, expanding them, and reinfusing them, this approach reprograms macrophages already […]

From T Cells to B Cells: The Next Generation of Personalized Cancer Vaccines

A research team at the Korea Advanced Institute of Science and Technology (KAIST) has developed a new artificial intelligence model that could change how personalized cancer vaccines are designed. For decades, most cancer vaccine strategies have focused on training the immune system’s T cells to attack tumors quickly and directly, which can shrink tumors but […]

Weizmann Institute Identifies Immunotherapy Targets in Drug-Resistant Prostate Cancer

Researchers from Israel’s Weizmann Institute of Science have unveiled a promising immunotherapy strategy that targets drug-resistant cancers by exploiting the very genetic mutations responsible for treatment failure. ​ The approach centers on a computational tool called SpotNeoMet, which scans large patient datasets to identify recurrent resistance mutations that generate neo-antigens, unique protein fragments displayed exclusively […]

Immunotherapy’s Hidden Power: Reprogramming Cancer Back to Normal

In a previous article, cancer reversion was introduced as the idea that malignant cells can be pushed back toward a more normal, less aggressive state instead of simply being destroyed. That earlier discussion focused mainly on epigenetic plasticity, differentiation therapy, and microenvironmental modulation as ways to coax cancer cells into behaving more like healthy tissue. […]

Allergy Cells to Deliver Oncolytic Viruses or Drugs and to Stimulate the Immune System

A team of scientists in China has found a way to turn the same type of cells that cause allergies into a new kind of weapon against cancer. Their work suggests that the body’s fastest immune reaction, normally blamed for hives and asthma, could be redirected to wake up the immune system inside tumors and […]